Publication:
Methylation of rar β is a new clinical biomarker for treatment in higher-grade gliomas

dc.contributor.authorAtlı, Emine İkbal
dc.contributor.authorKalkan, Rasime
dc.contributor.buuauthorToprak, Çiğdem
dc.contributor.buuauthorTOPRAK, ÇİĞDEM
dc.contributor.departmentBursa Uludağ Üniversitesi/Sağlık Hizmetleri Meslek Yüksekokulu.
dc.date.accessioned2024-11-05T07:52:34Z
dc.date.available2024-11-05T07:52:34Z
dc.date.issued2023-07-01
dc.description.abstractBackground: The dysregulation of various pathways and cellular processes contributes to the carcinogenic transition from low-grade gliomas to high-grade gliomas. The altered tumor microenvironment, altered epigenetic state, and high mutation heterogeneity are critical factors in glial tumors. The morphogen retinoic acid (RA) controls the homeostasis, regeneration, and development of the brain. RA receptor (RAR) gene methylation has been shown in different types of glial tumors. Aims and Objectives: This study assessed the RAR beta gene as a potential therapeutic target in gliomas. Materials and Methods: Using in silico methods, potential drugs targeting the RAR beta gene were compared based on temozolomide's effectiveness in treating gliomas. Results and Conclusion: Computational techniques can be used to identify drug-mediated pathways. This in silico study holds promise for RARB and RARB-targeted treatment strategies in gliomas.
dc.identifier.doi10.4103/nsn.nsn_26_23
dc.identifier.endpage+
dc.identifier.issn2636-865X
dc.identifier.issue3
dc.identifier.startpage152
dc.identifier.urihttps://doi.org/10.4103/nsn.nsn_26_23
dc.identifier.urihttps://hdl.handle.net/11452/47423
dc.identifier.volume40
dc.identifier.wos001107292600006
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherWolters Kluwer Medknow Publications
dc.relation.journalNeurological Sciences And Neurophysiology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectPromoter methylation
dc.subjectStem-cells
dc.subjectGlioblastoma
dc.subjectMgmt
dc.subjectTemozolomide
dc.subjectIdh1
dc.subjectMutations
dc.subjectPathways
dc.subjectTool
dc.subjectGlioma treatment
dc.subjectRar beta
dc.subjectTemozolomide
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectNeurosciences
dc.subjectNeurosciences & neurology
dc.titleMethylation of rar β is a new clinical biomarker for treatment in higher-grade gliomas
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication83bbbe44-6d9f-48cd-aa61-1e22f40f481c
relation.isAuthorOfPublication.latestForDiscovery83bbbe44-6d9f-48cd-aa61-1e22f40f481c

Files

Collections